title: Identification of specific chondroitin sulfate species in cutaneous autoimmune disease.
abstract: Cutaneous lupus erythematosus and dermatomyositis (DM) are chronic inflammatory diseases of the skin with accumulated dermal mucin. Earlier work has shown chondroitin sulfate (CS) accumulation within the dermis of discoid lupus erythematosus (DLE), subacute cutaneous lupus erythematosus (SCLE), and DM lesions compared with control skin. Immunohistochemistry for C4S revealed a greater density in DLE and DM lesions, whereas SCLE lesions did not differ from controls. Scleredema and scleromyxedema are attributed to increased hyaluronic acid, and lesional samples from these diseases also demonstrated accumulated dermal C4S. Interferon-γ and interleukin-1α, but not interferon-α, treatment of cultured dermal fibroblasts induced mRNA expression of CHST-11, which attaches sulfates to the 4-position of unsulfated chondroitin. These studies on possible CS core proteins revealed that serglycin, known to have C6S side chains in endothelial cells, had greater density within DM dermal endothelia but not in DLE or SCLE, following the pattern of C6S overexpression reported previously. CD44 variants expand the CS binding repertoire of the glycoprotein; CD44v7 co-localized to the distribution of C4S in DLE lesions, a finding not observed in DM, SCLE lesions, or controls. Because C4S and C6S have immunologic effects, their dysregulation in cutaneous mucinoses may contribute to the pathogenesis of these disorders.
authors.affiliation: New York University School of Medicine, New York, New York, USA.
authors.forename: Jessica S
authors.initials: JS
authors.lastname: Kim
authors.forename: Victoria P
authors.initials: VP
authors.lastname: Werth
mesh_terms: D002478:Cells, Cultured; D002809:Chondroitin Sulfates / Q000378:metabolism*; D003882:Dermatomyositis / Q000378:metabolism*; D042783:Endothelial Cells / Q000378:metabolism; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D018960:Hyaluronan Receptors / Q000378:metabolism; D007150:Immunohistochemistry; D007371:Interferon-gamma / Q000494:pharmacology; D053582:Interleukin-1alpha / Q000494:pharmacology; D008178:Lupus Erythematosus, Cutaneous / Q000378:metabolism*; D008179:Lupus Erythematosus, Discoid / Q000378:metabolism; D011509:Proteoglycans / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012592:Scleredema Adultorum / Q000378:metabolism; D053718:Scleromyxedema / Q000378:metabolism; D012867:Skin / Q000378:metabolism; D015238:Sulfotransferases / Q000235:genetics / Q000378:metabolism; D033921:Vesicular Transport Proteins / Q000378:metabolism
chemical_list: D018960:Hyaluronan Receptors; D053582:Interleukin-1alpha; D011509:Proteoglycans; D012333:RNA, Messenger; D033921:Vesicular Transport Proteins; C075430:serglycin; D007371:Interferon-gamma; D002809:Chondroitin Sulfates; C411659:CHST11 protein, human; D015238:Sulfotransferases